Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business seed financing

Cloverleaf Bio $33M Seed Financing

Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 10, 2026

Sentiment
5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The financing signals continued venture appetite for early-stage RNA therapeutics and validates industry interest from three major pharma venture arms at the preclinical stage, a modest positive for sentiment toward the biotech venture funding environment. Direct public-market impact is limited given Cloverleaf is private, though the participation of AbbVie, Eli Lilly and Company, and Boehringer Ingelheim highlights strategic interest in tRNA-based oncology platforms.

biotechnology pharmaceuticals venture capital

Cloverleaf Bio, an RNA therapeutics company spun out of Yale University and headquartered in New Haven, Connecticut, closed an upsized and oversubscribed $33 million seed financing round. The round was led by 4BIO Capital and included strategic participation from AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund, alongside Draper Gain International, Mission BioCapital, and American Cancer Society BrightEdge. The simultaneous participation of three major pharmaceutical venture arms at the preclinical stage reflects strong industry interest in the company's engineered transfer RNA (tRNA) platform, which is built around selective and durable inhibition of multiple RNA-modifying enzymes that cancer cells become abnormally dependent on as they proliferate. Proceeds will advance two lead programs: an inhibitory tRNA asset targeting hepatocellular carcinoma through early clinical testing, and an antibody-tRNA conjugate targeting colorectal cancer through preclinical development. The lead compound CLB-001 reportedly demonstrated greater potency and selectivity for cancer cells over healthy cells in preclinical studies, retained activity in cancer cell lines resistant to frontline chemotherapy and current-generation ADC payloads, and outperformed frontline standards of care in hepatocellular carcinoma and lung adenocarcinoma models at substantially lower doses. Animal tolerability studies reportedly showed no increases in markers of liver damage and no signs of systemic toxicity. Cloverleaf's early research was supported in part by funding from the United States — National Cancer Institute under the NIH SBIR/STTR program. The company was founded by Austin Draycott, Cole Lewis, and Wendy Gilbert.

95 Cloverleaf Bio raised seed financing
85 4BIO Capital led financing round Cloverleaf Bio
70 AbbVie invested in round Cloverleaf Bio
70 Eli Lilly and Company invested in round Cloverleaf Bio
70 Boehringer Ingelheim invested in round Cloverleaf Bio
40 Mission BioCapital invested in round Cloverleaf Bio
priv
The central entity of the event, securing $33 million in oversubscribed seed financing to advance its engineered tRNA cancer therapeutics platform. The capital extends its runway and validates its preclinical data, though it remains a private, early-stage company.
Importance 100.0 Sentiment 40.0
priv
Led the upsized and oversubscribed $33 million seed round, reinforcing its position as a specialist biotech venture investor backing frontier science.
Importance 85.0 Sentiment 25.0
stock
Its venture arm AbbVie Ventures participated strategically in the round, giving it early exposure to Cloverleaf's tRNA platform and potential optionality in RNA-based oncology.
Importance 60.0 Sentiment 10.0
stock
Participated in the round through its venture arm, gaining early strategic access to Cloverleaf's engineered tRNA cancer therapeutics.
Importance 60.0 Sentiment 10.0
priv
Its venture fund invested in the round, reflecting strategic interest in Cloverleaf's novel RNA therapeutics approach.
Importance 60.0 Sentiment 10.0
per
CEO and co-founder of Cloverleaf Bio, leading the company's financing and therapeutic development efforts.
Importance 45.0 Sentiment 5.0
govactor
Provided early federal funding through the SBIR/STTR program that was foundational to Cloverleaf's platform development.
Importance 40.0 Sentiment 5.0
priv
Participated as an investor in the $33 million seed round.
Importance 35.0 Sentiment 5.0
priv
Participated as an investor in the $33 million seed round.
Importance 35.0 Sentiment 5.0
ngo
Its BrightEdge venture arm participated in the seed round, supporting Cloverleaf's cancer therapeutic development.
Importance 35.0 Sentiment 5.0
per
Co-founder and Managing Partner at lead investor 4BIO Capital, articulating the investment thesis behind the round.
Importance 30.0 Sentiment 5.0
per
Chief Scientific Officer and co-founder of Cloverleaf Bio, contributing RNA biology expertise to the platform.
Importance 25.0 Sentiment 5.0
per
Scientific Advisory Board Chair and co-founder of Cloverleaf Bio, providing RNA biology expertise.
Importance 25.0 Sentiment 5.0
govactor
Parent agency of the United States — National Cancer Institute, which funded Cloverleaf's foundational research.
Importance 20.0 Sentiment 0.0
per
Director at AbbVie Ventures, commenting on AbbVie's early and ongoing support of Cloverleaf.
Importance 20.0 Sentiment 5.0
+ 6 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.